CalciMedica Announces Pricing for Public Offering of Common Stock Via Investing.com

0 0 3 minutes read

CalciMedica Announces Pricing for Public Offering of Common Stock Via Investing.com

LA JOLLA, Calif., October 30, 2024 /PRNewswire/ — The company CalciMedica, Inc. (“CalciMedica“or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing calcium channel blocker (“CRAC”) therapies for acute and chronic disease and immunologic disease, today announced the pricing of calcium . an underwritten public offering of 2,720,000 shares of its common stock at a price to the public $3.75 per share. The Company's net proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $10,200,000. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 408,000 shares of its common stock at the public offering price, less discounts and commissions. All shares will be sold by the Company. The offering is expected to close on or about November 1, 2024subject to the satisfaction of the closing conditions of the culture.

Jones is acting as the sole book-running manager for the offering.

The underwritten public offering was made pursuant to a shelf registration statement on Form S-3 (File No. 333-273949) (including the base prospectus) previously filed. Securities and Exchange Commission (the “SEC“) to August 11, 2023 and declared valid by SEC to August 18, 2023. The first supplement to the prospectus and the accompanying prospectus relating to and describing the terms of the underwritten public offering were filed in SEC to October 30, 2024. The final prospectus supplement relating to the offering will be filed with SEC and will be available at SEC fees website at www.sec.gov. If available, electronic copies of the final prospectus supplement and the accompanying prospectus relating to the underwritten public offering may also be obtained by contacting: JonesTrading Institutional Services LLC, Attn: Equity Capital Markets, 325 Hudson (NYSE:) Street6th Floor New York, New York 10013; email: ecm@jonestrading.com.

This press release does not constitute an offer to sell or solicitation of an offer to buy, and there will not be any sale of these securities in any state or place where such offer, solicitation or sale would be unlawful prior to registration or qualification. subject to the securities laws of any state or jurisdiction.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibitors for the treatment of inflammatory and immunologic diseases. CalciMedica proprietary technology aims to block CRAC channels to modulate the immune response and protect against tissue cell damage, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed clinical efficacy trials. CalciMedica announced data from a Phase 2b study (called CARPO “NCT04681066) in AP patients with SIRS and completed a Phase 2 trial (called CARDEA “NCT04345614) in patients with COVID pneumonia. The company is currently conducting a Phase 2 trial (named KOURAGE “NCT06374797) in patients with AKI with associated AHRF with data expected in 2025 and continues to support an ongoing Phase 1/2 trial (named CRSPA “NCT04195347) in patients with AIPT with data. expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.

Forward-Looking Statements
Any statements in this press release about its future expectations, plans and prospects CalciMedicaincluding statements regarding the timing and completion of the underwritten public offering, and other statements containing the words “anticipate,” “believe,” “estimate,” “anticipate,” “intend,” “may,” “plan,” “predict,” “project, ” “intended,” “potential,” “will,” “may,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of Private Securities. Criminal Reform Act 1995. Actual results may differ materially from those indicated by such forward-looking statements for a variety of important reasons, including: CalciMedica the inability, or the inability of the underwriter, to satisfy the closing conditions of the underwritten public offering; and economic, business, competitive, and/or regulatory factors affecting the business CalciMedica generally. Additional risks and uncertainties that could cause actual results and outcomes to differ materially from those projected by the forward-looking statements are included under the caption “Risk Factors” on. CalciMedica Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filled with SEC to August 12, 2024 and other episodes CalciMedica do with SEC from time to time and is available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date they are made. CalciMedica undertakes no obligation to update such statements to reflect events occurring or conditions existing after the date on which they are made, except as required by law.